logo
Share SHARE
FONT-SIZE Plus   Neg

Vicor Forecast Q4 Profit At Essentially Breakeven Level - Quick Facts

Vicor Corp. (VICR) Monday said it expects fourth-quarter earnings in an essentially break-even level, flat with prior-quarter. Based on existing backlog, the company has forecast a loss for the first quarter of 2013.

The company has been experiencing eight consecutive quarters of declining earnings, largely attributable to weak demands, lower volumes and higher expenses.

"In the fourth quarter of 2012, our bookings activity has slowed; through November 23. This reduction in orders has caused us to reassess our expectations for revenue and earnings for the fourth quarter of 2012 and the first quarter of 2013, " said Patrizio Vinciarelli, Vicor's Chairman of the Board and CEO.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT